Analysts defend Intuitive Surgical as docs defend robot-assisted surgery

Intuitive Surgical's da Vinci robot-assisted surgical system

Updated March 18, 2013, at 2:15 p.m. with a correction.

Intuitive Surgical (NSDQ:ISRG) gained back a few points on Wall Street today as analysts noted movement among minimally invasive surgeons arising to defend robot-assisted surgery.

A group of surgeons over the weekend issued a public letter chiding American College of Obstetricians & Gynecologists president Dr. James Breeden over an editorial highlighting cost concerns and a perceived lack of evidence behind the hype around robot-assisted procedures.

"We see a failure in ACOG’s ability to embrace the education of minimally invasive surgery," the doctors wrote. "Robotic surgery is an enabling technology that has transformed our ability to operate in a more efficient, controlled surgical field and master complex anatomical environments. It has allowed us to extend a level of quality surgical care to our patients that is exceptionally more diverse and complete than was ever possible with traditional methods of surgery."

The letter came in response to Breeden’s letter, published last week by ACOG, which called into question the cost-to-benefit ratio for expensive robot-assisted surgical procedures.

"While there may be some advantages to the use of robotics in complex hysterectomies, especially for cancer operations that require extensive surgery and removal of lymph nodes, studies have shown that adding this expensive technology for routine surgical care does not improve patient outcomes," Breeden wrote. "Consequently, there is no good data proving that robotic hysterectomy is even as good as – let alone better – than existing, and far less costly, minimally invasive alternatives."

Robots in the operating room are generally connected with lower recovery times, but the technology often requires expensive instruments, and the systems themselves come with a heavy price tag. Breeden’s letter was not the 1st to call out the technology for its extra expense and perceived lack of sufficient clinical evidence.* Some doctors and rival device makers have criticized the lack of sufficient clinical data directly comparing robot-assisted surgery to other minimally invasive procedures.

The coalition of doctors defending robot-assisted surgery called Breeden out for "the lack of evidence" that they claimed underpinned the ACOG letter. Breeden compared robot-assisted surgery to other minimally invasive procedures, but the coalition claimed that most physicians can’t offer such approaches to their patients.

Breeden’s comments, the coalition said, addressed cost concerns that hadn’t properly been studied and failed to consider the indirect costs, such as extended hospital stays and time away from work, associated with traditional procedures. Robotic systems have "enabled minimally invasive surgery for nearly every 1 of our patients, and >100,000 more women were offered a minimally invasive hysterectomy in 2012 as compared to 2005 as a direct result of the robotic platform," according to the letter.

Breeden’s letter helped spur another in a string of sell-offs for Intuitive Surgical’s shares, but it’s conclusions were very similar to those published earlier in the Journal of the American Medical Assn. That report questioned the value of robot-assisted hysterectomy in terms of the increased cost and the benefit to patients.

"Because both laparoscopic and robotic-assisted hysterectomy are associated with low complication rates, it is unclear what benefits robotically assisted hysterectomy offers," according to the February report. "When the innovation being advertised is of questionable advantage, direct-to-consumer promotion may only fuel unnecessary utilization."

The coalition of doctors took exception to indications that the rise of robot-assisted surgery was due in any way to "deceptive marketing practices," calling the notion an affront to physicians and their informed clinical opinions.

The group concluded by asking ACOG to "reflect upon your statement and reconsider an opinion based on incomplete data," calling on other minimally invasive physicians to help shore up the holes in research surrounding robot-assisted surgery.

"In the light of the recent flurry of negative news based on the early experience with robotic surgery, we robotic surgeons are now compelled to collaborate and produce outcomes research to document the benefits we are seeing clinically and to comprehensively evaluate the "cost" of this technology," according to the letter.

Neither Breeden’s letter nor the response mentioned Intuitive Surgical by name, but the company is generally perceived as the face of robot-assisted surgery. Intuitive Surgical’s da Vinci system has a corner on much of the market, including minimally invasive hysterectomies and prostatectomies.

The medical device company has had a run of bad luck lately as a few stark headlines dragged shares down more than 20% over the course of this month. ISRG shares dropped 11% in 1 day on February 28 on news that the FDA was conducting a survey of da Vinci robot users, asking for details about an apparent rise in complications associated with the device and seeking tips on best use and training.

Intuitive Surgical later explained that what appeared to be a rise in da Vinci complication rates was actually a reflection of new reporting practices rather than a change in product performance.

"In September 2012, Intuitive Surgical revised its [Medical Device Reports] practices, resulting in increased reports of device malfunction MDRs, the vast majority of which were related to instruments and not to systems," the company said. "None of these device malfunction MDRs involved reportable injuries or deaths."

Analysts at Goldman Sachs also came to the defense of the company, maintaining a "buy" rating on ISRG shares and projecting an end to the nosedive that dragged the stock price down nearly 20% since the end of February. ISRG shares opened at $573.44 on February 28, but sank to $509.89 by the end of the day on news of the FDA probe. Shares have bounced up and down over the course of the month, closing at $459.44 on Friday, March 16.

The physician defense and the positive analyst outlook may have helped turn the tide. Shares gain 4.4% today and were trading at $479.40 as of about 11:40 a.m. EST.

The plunge, while bad news for current shareholders, may be an opportunity for new investors.

"ISRG is extremely oversold and represents an incredible buying opportunity," according to StockTalks at "The recent sell-off is due to fear, and when the truth behind these fears is realized, the stock will undoubtedly rise."

*Correction: This article mistakenly stated that the da Vinci surgical system’s instruments are designed for 1-time use. Most are usable 10 times prior to replacement, according to the company.

RSS From Medical Design & Outsourcing

  • Molex delivers ISO 13485-compliant, medical-grade surgical cables from its class 100,000 clean room facility
    Molex, LLC operates a fully ISO 146441-1:1999 Class 8-certified clean room, satisfying strict particulate contamination levels specified by ISO-compliant requirements. Located in Thailand, the facility has less than 100,000 particulates (≥0.5µm) per cubic foot of air and manufactures a variety of ISO 13485-compliant medical cables and surgical cables used in operating theatres, hospitals, laboratories and […]
  • Swept-Source OCT: Patent license agreement between Massachusetts General Hospital and Heidelberg Engineering
    Heidelberg Engineering has entered into a patent license agreement with Massachusetts General Hospital (MGH) in Boston. The agreement grants global and exclusive rights to 77 basic patents and patent applications which relate to swept-source OCT technology and its application in ophthalmology. Spectral domain OCT has become indispensable to eye care professionals worldwide to diagnose and […]
  • MIT’s MultiFab presents a stark challenge to incumbent 3D Printer manufacturers’ hardware, software, and business Models
    MIT’s Computational Fabrication Group recently announced the MultiFab, a low-cost 3D printer that can combine up to 10 different resins in one part and also includes a 3D scanning system to identify and fix errors during production. According to Lux Research, these capabilities are rare in commercial 3D printers today due to the manufacturers’ need […]
  • AVX releases Accu-P MP medical grade film chip capacitors for medical devices
    AVX Corporation, a leading manufacturer of passive components and interconnect solutions, has released a new series of thin film chip capacitors specifically designed to meet the demanding performance specifications for implantable medical devices. Delivering extremely tight capacitive tolerances, exceptionally repeatable performance, and remarkably low ESR and high Q at high frequencies—including VHF, UHF, and RF […]
  • RIVANNA commences manufacturing of its Accuro device
    Rivanna Medical announced that it has begun manufacturing its FDA-cleared Accuro device, a handheld and untethered smart-phone-sized device that is designed to guide spinal anesthesia with automated 3D navigation technology in addition to ultrasound imaging of abdominal, musculoskeletal, cardiac and peripheral vascular anatomies. The product will be launched at the ASA annual meeting in San […]
  • FDA seeks public input on Quality Metrics guidance
    by Oliver Wolf, Senior Product Manager, MasterControl In line with the general shift towards risk-driven approaches in the quality management world, FDA is now taking steps towards applying those same principles to its own auditing schedule. At the end of July, the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation […]
  • First ‘Ear Wear’ for Active Adults Debuts with MDHearingAid FIT
    If you’ve burned out your ears with earbuds, headphones or decades of other audio abuse but aren’t ready for your grandmother’s hearing aids, not to worry! The new MDHearingAid FIT gets you back in the game with a tiny, FDA-registered, one-size-fits-most solution that doesn’t block your ear canal like old-fashioned in-the-ear hearing aids. The FIT feels […]
  • CardioGenics enters into manufacturing agreement with Ontario-based Plasticap
    CardioGenics Holdings, developer for the In-Vitro-Diagnostics (“IVD”) testing market, announced that it has entered into a manufacturing agreement with Plasticap of Ontario, Canada, pursuant to which Plasticap will manufacture CardioGenics’ proprietary self-metering cartridges for its QL Care analyzer. The term of the agreement is three years and the purchase price for each cartridge shall be […]
  • MTD Micro Molding releases micro materials menu
    MTD Micro Molding, a long-time leader in micro-injection molding, has released an updated “Materials Menu” of materials that can be successfully micromolded to help guide engineers at medical device companies. Material selection is a crucial step in product manufacturability. The correct material drives tolerance, dimension, strength, usabality, speed-to-market, design, critical features, and cost. Through MTD’s […]
  • MedTech Chat: Elastic technology for drug delivery
    Dr. Zhen Gu and Dr. Yong Zhu from North Carolina State University are both co-senior authors of a research paper describing their recent work. Dr. Gu, Dr. Zhu and other researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed a drug delivery technology that consists of an […]
  • B. Braun’s OEM Division offers large bore normally closed low-pressure check valves
    Infusion therapy and pain management device manufacturer B. Braun said today it is offering normally closed large-bore low-pressure check valves through its valve-focused contract manufacturing OEM division. The valves, offered by Bethlehem, Pa.-based B. Braun, are designed for the intermittent injection of fluids during medical treatment and open automatically when pressure is applied. The newly […]

Leave a Reply